C. Whitehead

发表

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

J. Warmus, J. Sebolt-Leopold, Chunhong Yan, 2004, Nature Structural &Molecular Biology.

Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.

S. Jolly, A. Rehemtulla, C. Van Waes, 2012, Neoplasia.

4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.

Daniel F Ortwine, J. A. Spicer, W. Denny, 2007, Journal of medicinal chemistry.

2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).

J. Warmus, A. Bridges, W. Leopold, 2008, Bioorganic & medicinal chemistry letters.

Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.

J. Pandit, C. Whitehead, Cindy Spessard, 2013, Bioorganic & medicinal chemistry letters.

Corrigendum: Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

J. Warmus, J. Sebolt-Leopold, Chunhong Yan, 2005, Nature Structural &Molecular Biology.

Oncogenic Mutants of MEK1: A Trilogy Unfolds.

J. Sebolt-Leopold, C. Whitehead, J. Maust, 2018, Cancer discovery.

Systematic analysis uncovers SYK dependency in NF1LoF melanoma cells

M. Fallahi-Sichani, J. Sebolt-Leopold, C. Whitehead, 2022, bioRxiv.

Cisplatin Induces Bmi1 and Enhances the Stem Cell Fraction in Head and Neck Cancer

A. Chinnaiyan, D. Beer, Guoan Chen, 2015 .

Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.

B. Ross, A. Rehemtulla, J. Sebolt-Leopold, 2015, Bioorganic & medicinal chemistry.

Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.

Howard Miller, J. Pandit, C. Whitehead, 2013, Bioorganic & medicinal chemistry letters.

Deciphering the Complexity of MEK Mutations in the Clinic

J. Sebolt-Leopold, C. Whitehead, 2020, Cancer Research.

Destabilization of the Epidermal Growth Factor Receptor (EGFR) by a Peptide That Inhibits EGFR Binding to Heat Shock Protein 90 and Receptor Dimerization*♦

A. Rehemtulla, T. Lawrence, D. Ray, 2013, The Journal of Biological Chemistry.

KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation.

A. Chinnaiyan, D. Beer, Guoan Chen, 2014, Neoplasia.

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

R. Mohammad, R. Messmann, A. Al-Katib, 2014, Cancer Chemotherapy and Pharmacology.

Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts.

A. Rehemtulla, T. Lawrence, D. Ray, 2014, Neoplasia.

Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

M. Fallahi-Sichani, J. Sebolt-Leopold, C. Whitehead, 2022, Cancer research.